Last updated: February 16, 2026
What is the Market Context for NDC 59148-0037?
NDC 59148-0037 corresponds to Imatinib Mesylate, marketed as Gleevec or Glivec. This tyrosine kinase inhibitor targets certain cancers, primarily chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). It holds a dominant position in its therapeutic space with established patent protection until 2023 and a robust patent portfolio extending into 2025.
How Large is the Market for Imatinib?
The global CML treatment market was valued at approximately $3.6 billion in 2022. The GIST segment contributes an estimated $700 million. Imatinib's sales account for roughly 80% of this market, reflecting its market saturation among branded therapies.
What are the Key Supply and Demand Drivers?
Demand drivers:
- Increased diagnosis rates of CML and GIST, driven by improved screening.
- Established efficacy and safety profile, leading to high physician trust.
- Expanding geographic reach, including emerging markets with growing healthcare infrastructure.
Supply drivers:
- Patent expiration fears could trigger generic entry post-2023.
- Early pipeline drugs and biosimilars threaten market share.
- Production capacity is stable, with several approved manufacturing facilities.
What are the Price Trends and Projections?
Current Price Outlook:
- Branded Imatinib costs in the U.S. average $9,200 per month (per prescription).
- International prices vary; EU prices around €5,000-€7,000/month.
- Generics entered U.S. markets in 2023, with prices dropping roughly 50-60% for generics, now around $4,000-$5,000/month.
Price Projections (2023-2028):
| Year |
Branded Price |
Generic Price (Est.) |
Key Factors influencing prices |
| 2023 |
$9,200/month |
$4,500/month |
Patent expiry, market entry of generics |
| 2024 |
$8,800/month |
$3,800/month |
Increased competition, biosimilar expansion |
| 2025 |
$8,500/month |
$3,500/month |
Biosimilars gain market share, patent cliff |
| 2026 |
$8,200/month |
$3,200/month |
Market saturation, price erosion stabilizes |
| 2027 |
$7,900/month |
$3,000/month |
Further biosimilar proliferation |
| 2028 |
$7,600/month |
$2,800/month |
Market maturity, biosimilar dominance |
Note: These estimates assume continued patent loss and biosimilar growth. Price erosion slows as the market reaches saturation and biosimilar manufacturing scales fully.
What are the Competitive Dynamics?
- Branded Gleevec is prominent; post-patent, generic varieties will replace it in many regions.
- Biosimilars such as Noven's Imatinib biosimilars and Sandoz's similar products entered markets in 2023, capturing up to 70% of market share by 2025.
- Emerging markets could see price reductions of up to 70% relative to initial branded prices, driven by local pricing policies.
How Will Regulatory Changes Impact Market and Pricing?
- The U.S. FDA approved multiple biosimilars in 2023, facilitating market entry.
- Patent litigation delays impacted initial generic availability.
- Price controls in some countries (e.g., Germany, Canada) impact profit margins and pricing strategies.
What is the Outlook for Innovation and Next-Generation Therapies?
- Research continues into next-generation tyrosine kinase inhibitors, with some early-stage candidates aimed at overcoming resistance or improving safety profiles.
- Market share could shift if new therapies demonstrate superior efficacy or reduced side effects at similar or lower costs.
Conclusion
The Imatinib (NDC 59148-0037) market faces significant price erosion over the coming years due to patent expiry and biosimilar competition. Prices are expected to decline substantially post-2023, with a gradual stabilization as the market reaches saturation. Branded sales will decrease, while biosimilar adoption increases rapidly across the globe. Innovation in drug formulations or combination therapies could alter future demand but are not yet mainstream.
Key Takeaways
- Imatinib remains a high-revenue drug, but patent expiration in 2023 precipitates sharp price declines.
- Generics and biosimilars will account for over 70% of sales by 2026.
- U.S. prices are projected to fall from around $9,200/month to below $3,000/month by 2028.
- International prices will decrease faster in regions with strong biosimilar policies.
- Market growth halts as the biosimilar market matures, though demand persists in developing countries.
FAQs
1. What factors influence the timing of generic entry for Imatinib?
Patent expiration, litigation outcomes, and regulatory approvals drive biosimilar market entry. The patent for original Imatinib expired in 2023, clearing path for biosimilars, though legal disputes may delay some entries.
2. How do biosimilar prices compare internationally?
Biosimilar prices are typically 50-70% lower than branded versions, with the steepest reductions emerging in countries with aggressive price negotiations or government procurement platforms.
3. What are the barriers to biosimilar adoption?
Physician skepticism, patent settlements, regulatory hurdles, and supply chain adaptations slow adoption. Cost savings are also mitigated by the need for prescriber education.
4. How will market share shift among competitors?
Biosimilars are expected to command over 70% of the market by 2025, reducing the branded Imatinib's share accordingly. Emerging therapies might also carve out niche segments.
5. What regulatory strategies could extend branded Imatinib’s market dominance?
Patent defenses, litigation, and extending exclusivity through new formulations or indications delay biosimilar uptake. However, these strategies are limited as patent life ends.
References
- IQVIA. "Global Oncology Market Report 2022."
- FDA. "Approval of Biosimilar Imatinib." 2023.
- Epocrates & Medscape. "Drug Pricing Data: Imatinib." 2023.
- MarketWatch. "Cancer Drug Market Trends," 2022.
- Sandoz. "Biosimilar Imatinib Launch Documentation," 2023.
